Stay updated with breaking news from Roivant Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
By Adria Calatayud Roche Holding has agreed to buy Telavant Holdings from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion that will give it...
Swiss health care company Roche on Monday announced it would acquire Telavant Holdings in a $7.1 billion transaction.
Roche will gain the rights to Telavant’s drug candidate for inflammatory disease in the U.S. and Japan. Photograph by Stefan Wermuth/Bloomberg Swiss pharmaceutical company Roche said Monday it has agreed to buy
1897 Dainippon Pharmaceutical 1944 ...
The Swiss pharma giant said it will begin late-stage trials on the experimental antibody therapy “as soon as possible” to help bring it to patients suffering from inflammatory bowel disease.